



# **INTEGRATED HEMATOLOGY**

---



# Hematology Basics



1st Hb - E/M



~1% of circulating RBCs are reticulocytes



Preferred site for BMA/ BMB:  
 Adult- PSIS  
 Child- Tibia  
 Low Platelet CI?: No / <20k \*transfuse

'RPI'

$$\text{Reticulocyte Production Index} = \frac{(\text{Retic \%}) \times (\text{Hct} / 45)}{\text{Maturation Factor}}$$

("Retic Index")

| Hematocrit (Hct) | Maturation Factor |
|------------------|-------------------|
| ≥ 40%            | 1.0               |
| 30 - 39.9%       | 1.5               |
| 20 - 29.9%       | 2.0               |
| < 20%            | 2.5               |

Different references contain slightly different versions of this table.

# RBC shapes and disorders

Fe list bro






Elliptocytes : HE → mc : Spectrin

Spherocytes : HS → mc : Ankyrin  
 most severe : Spectrin

MCHC ↑ → AIHA (mc), G6PD

EYM : jaundice, splenomegaly

HS → BIRMB  
 EMA binding test  
 OF ↑



target = codocyte : Thalassemia


Drepanocyte = SCA  
 ↓  
 auto-splenectomy  
 Howell Jolly bodies

agglutination  
 AIHA → warm → CLL, SLE, penicillin, methyl dopa  
 (194)  
 DCT ⊕  
 cold → Mycoplasma, EBV  
 (19m)

Megaloblastic anemia  
 fine basophilic stippling


B12 def / folate def /  
 • knuckle pigmentation  
 SACD  
 • ileal D  
 • Pernicious A  
 • gastrectomy  
 • vegans  
 • junk food  
 • alcoholics  
 • pregnancy

NESTROFT  
 DROTTIC  
 ACIDURIA  
 (UMP synthase)



Trillaseemia NORMAL

CLL : AIHA + ITP  
 EVAN'S Sr



Acantocytes / SPUR cells } Abetalipoproteinemia (MTTP gene)  
vit E def

regular

Burr cells / Echinocytes

Burns, Renal failure  
Pyr kinase def

tear drop / dacryocytes

Myelophthisis / Myelofibrosis

Schistocytes / Helmet cells

MAHA  
angiopathic HA

Microangiopathic

macroangiopathic

DISEASE: HUS / TTP / DIC / HELLP  
ADAMTS13  
neuro sym (+)

Prosthetic valves

Bite cells

Heinz body

denatured Hb  
crystal violets

Fluorescent Spot Test




G6PD deficiency

HMP shunt → INH/EVH

NADPH → auto fluorescence

oxidative stress  
Fava beans  
Dapsone PR  
Sulfonamides

Basophilic stippling (Coarse)



PRUSSIAN BLUE / PERL'S

Sideroblastic A  
Ringed Sideroblast

ALA synthase (XLR)

B6 def (TNU)

Pb  
ALA dehydr Ferroxidat

# Anemias

**Microcytic**  
(MCV < 80 fL)

**Normocytic**  
(MCV 80-100 fL)



**Macrocytic**  
(MCV > 100 fL)

*S I T A*  
Sideroblastic  
IDA  
Thalassemia  
AOCAD

**Nonhemolytic**  
(low reticulocyte index)

**Hemolytic** RPI ↑  
(high reticulocyte index)

**Megaloblastic**

**Nonmegaloblastic**

**DNA affected**

- Defective DNA synthesis
  - Folate deficiency
  - Vitamin B<sub>12</sub> deficiency
  - Orotic aciduria
- Defective DNA repair
  - Fanconi anemia

- Diamond-Blackfan anemia
- Liver disease
- Chronic alcohol overuse

Aplastic anemia / PCA  
CKD  
EPO ⊖

**Intrinsic**

**Extrinsic**

*Radial ray anomaly*


|                                   | IDA | AOCAD | Sideroblastic |
|-----------------------------------|-----|-------|---------------|
| Serum iron                        | ↓   | ↓     | ↑             |
| Transferrin or TIBC               | ↑   | ↓     | ↓             |
| Ferritin                          | ↓   | ↑     | ↑             |
| % transferrin saturation (N): 33% | ↓↓  | ↓     | ↑↑            |


Hb < Thalassemia  
SCA

Membrane -HS/HE  
↓  
PNH \* acquired



enz T G6PD  
Pyruvate kinase

AIHA  
MAHA





**PNH** Paroxysmal nocturnal hemoglobinuria




IOC: Flow cytometry - mcc of death

- Intravascular hemolysis
- Pancytopenia
- Thrombosis-Budd Chiari syndrome
- LAP score low - less
- Aplastic anemia, Leukemia
- Ham's acidified serum test, sucrose lysis test
- GEL CARD TEST - Screening
- Rx-Eculizumab  $\underline{\underline{C5}}$


# Anemia

$\frac{MCV}{RBC}$   
**Mentzer index** IDA vs **Thalassemia minor**  
 >13 <13  
**RDW:** ↑ -  
 Confirmatory test for thalassemia minor: **HPLC**  
**HbA<sub>2</sub> (<2% ↓)** **HbA<sub>2</sub> (α2δ2 ↑)**


**EMH**  
 Extramedullary  
 Hematopoiesis



microcytic hypochromic  
 anisocytosis poikilocytosis



AA → (N) adult  
 AF → (N) newborn  
 AS → **SC trait**  
 SS → SCA  
 AC → HbC trait  
 CC → HbC  
 SC → HbSC



**C S F A**  
 "A Fat Santa Claus"

Glu → Valine: **HbS**  
 Glu → Lysine: **HbC**  
 Chr 16 deletion: α Thalassemia --/--  
 Chr 11 Splicing mutation: β Thal --/--  
 IVS1-5 G→C (MC India)

**SICKLE CELL ANEMIA:**  
 Glutamic acid  
 Hydroxyurea, Voxelotor → ↓ sickling ↑ HbF  
 Crizanlizumab p-selectin ⊖

# Blood cells

"Lt shift"



**Myeloblast**


Auer rods



**Promyelocyte**




**Myelocyte**




**Metamyelocyte**



**Band/ Stab**



**Neutrophil**




**LAP score**

LOW

HIGH


**CML / PNH**

**Leukemoid**




**E**

↑ allergy  
↑ parasitic



**B**asophil

↑ → **CML**  
Tol blue\*



monocyte




**L**ymph

HIT



**Plt**

Plasma



Golgi  
Cartwheel chromatin


**Dense / delta granules: CASH**

$Ca^{2+}$  / ADP / serotonin / histamine

Hermansky Pudlak syndrome

**Alfa granules: fibrinogen fibronectin**

→ **PF4** vWF  
Grey platelet syndrome




# Approach to Pancytopenia

## HSM+

HYPERCELLULAR MARROW ✓

Leukemia


DRY TAP +



Myelofibrosis


## HSM -

HYPERCELLULAR MARROW



Myelodysplasia  
 Paw ball megakaryocyte  
 Pseudo Pelger-Huet anomaly

DRY TAP + BMB:



(N) 50% cell 50% fat

APLASTIC anemia


Idiopathic (MCC) / Viral/diuge

# Approach to Leukemia

## CHRONIC

Lymphocytic

**CLL** =  
SLL




Convent school girl

Myeloid origin

**CML**

basophilia ↑




College party / garden party

Binet / Rai staging

Chronic : < 10% BL  
Accelerated : 10-20%  
Blastic : > 20% BL

Ph chr - 210KD  
t(9;22)  
ABL BCR




Pseudo-Gaucher cell

loc: FISH


## ACUTE

CHILD ALL



Lymphoblast  
PAS (+) 'dot-blot'

ADULT AML



Nucleus ↑↑  
cytopl ↑↑  
AUER RODS

Myeloblast  
MPO / SBB (+)

<1yr, >10yr ☹️  
T cell - Acid phosphatase +  
NOTCH mutation  
Mediastinum, Brain, Testes  
L2  
Hypodiploidy  
t(9;22) 190KD  
t(4;11)  
Ph chromosome


Pre B cell 😊  
L1  
Hyperdiploidy  
t 12;21  
TRISOMY 4,7,10

ALL - 190KD  
CML - 210KD  
CNL - 230KD

IDC: Flow cytometry  
TOC: Fludarabine

MC in children: **ALL**  
 MC in down syndrome: **ALL**  
 MC in downs (<3yr): **AML M7**  
 MC in adults: **AML**  
 MC with radiation: **AML**  
 MC in elderly: **CLL**  
 MC in west: **CLL**  
 Not associated with radiation: **CLL**  
 Associated with deletion-13q: **CLL**

**SPLENOMEGALY + PANCYTOPENIA**  
**DRY TAP +**  
**TRAP+**  
**BRAF** mutation  
 Markers: **Annexin A1** (most sp) vs **Ⓜ**  
 ↓  
**apoptosis**  
**CD11c, 25, 103**  
**DOC- cladribine**



**WHO- FAB → AML**

- M0:** Undifferentiated acute myeloblastic leukemia (5%)
- M1:** Greater number of myeloblasts with <10% granulocytic differentiation.
- M2:** Myeloblasts in great number with granulocytic differentiation >10% , NSE <20%.
- M3:** Promyelocytes that are hyper granular with many Auer rods on CAE or Wright-stain and variant form cells with reniform nuclei, multilobed or bibbed, primeval cells with multiple Auer rods or relative scarcity of Hypergranular promyelocytes.
- M4:** >20% but <80% NSE-butyrate positivity in Monocytic cells
- M5:** Monocytic cells with >80% NSE positivity. (a) Monocytic differentiated (b) Monocytic, differentiated.
- M6:** >30% myeloblasts with more than 50% erythroblasts eliminating the erythroid cells.
- M7:** Acute megakaryoblastic leukemia <5%

**(MC) t(8;21)**

**mc → chloromas**



**Faggot cells**  
**APML**

**t(15;17) (APML; RARA)**  
**DIC**  
**Rp: ATRA** → **As<sub>2</sub>O<sub>3</sub>**


**· Mycoplasma**  
**· M. ferus**

**Fried egg appearance**

**· Oligodendroglioma: 1p/19q**  
**· Seminoma** **co del<sup>17</sup>**

**NSE (+)**  
**"leukemia cutis"**  
**inv 16**

**· dry tap**  
**· Down's 5<sub>a</sub>**



# Approach to NHL

CD 19/20+ : **B cell** CD 3+ : **T cell**

CD 10+  
BCL6+



CD 10+  
BCL-2+ ☺

CD 5+

CD5-  
CD 23-  
CD 10-


MC NHL  
MC aggressive  
MC extranodal  
EBV (+)

**Burkitt**  
C-myc  
Ki 67 100%



"waxing and waning" LN

CD 23+ CLL/SLL  
Cd 200+ SLL  
DELETION 13q



CD 23-  
CYCLIN D1+  
SOX 11+  
Cleaved/buttrock cells  
Lymphomatoid polyposis


↓  
Marginal/  
MALToma

Mantle

**DLBCL**  
"Richter" transfr<sup>m</sup>  
SLL/CLL → DLBCL

Best prognosis  
centrocyte, centroblast  
**FOLLICULAR**

Smudge cells





starry sky  
endemic (Jaw)  
sporadic (abdomen)

8 = Burkitt  
11  
14  
18 Bcl 2

t(8;14)  
t(8;22)  
t(2;8)

t(11;18) → Marginal zone  
t(14;18) → Follicular  
t(11;14) → Mantle




epidemo  
tropism



clover leaf

HTLV

retrovirus



Cerebriform



Sezary Sx

Mycosis fungoides:  
cut T cell lymphoma

↳ Panthier's mass

Hallmark cell

Donut cell

Anaplastic large cell

# Approach to Hodgkin's lymphoma

REGIONAL LN


CD20 +  
CD45+  
EMA +  
BCL-6 +  
EBV LMP -

POPCORN CELL



Lymphocyte  
predominant  
Best prognosis

COLLAGEN  
NODULES,  
LACUNAR CELL



Lacunar cells  
Nodular sclerosis

CD 15 +  
CD30 + most sensitive  
PAX5 most specific  
EBV LMP +

BACKGROUND  
MIXED,  
CLASSICAL RS



Mixed  
cellularity  
mc India

Classical  
RS cell

BACKGROUND  
LYMPHOCYTE,  
MONONUCLEAR RS

Lymphocyte  
rich

LOW LYMPHOCYTE,  
PLEOMORPHIC /  
MUMMIFIED RS

Lymphocyte  
depleted

# Myeloproliferative disorders

|                               | RBC | WBC | PLATELET | JAK2 MUTATIONS            |
|-------------------------------|-----|-----|----------|---------------------------|
| Polycythemia vera<br>EPO: (↓) | ↑↑  | ↑   | ↑        | (+)(+) JAK2 ⊖ Ruxolitinib |
| Essential Thrombocytosis      | -   | -   | ↑↑       | 30-50%                    |
| CML                           | ↓   | ↑↑  | ↑        | (-)                       |
| MYELOFIBROSIS                 | ↓   | ↓   | ↓        | 30-50%                    |




erythromelalgia (ET)



Staghorn megakaryocyte

PV: aquagenic pruritus

# Hodgkin's lymphoma STAGING




Ann-Arbor Staging





# Multiple myeloma

monoclonal

- C** = increased calcium levels (greater than 11.5 mg/dL)
- R** = renal insufficiency (creatinine greater than 2 mg/dL or creatinine clearance less than 40 mL/min)
- A** = anemia (hemoglobin less than 10 g/dL or 2 g/dL less than normal)
- B** = presence of bone lesions (presence of one or more osteolytic lesions seen on skeletal radiography, whole-body MRI, or whole-body FDG PET/CT)




"Punched out"



## MM DEFINING BIOMARKERS

SLIM

- S** = greater than or equal to sixty percent clonal plasma cells in the bone marrow
- Li** = involved/uninvolved free light chain ratio of 100 or more with the involved FLC being greater than or equal 100 mg/L → Bence Jones proteinuria
- M** = MRI with more than one focal marrow lesion



1° → AL

Mulberry/Mott cells

Flame cells

Russel body- Intracytoplasmic

Dutcher body- Intranuclear

CD38, CD138

↓  
Plasma cell

• Lenalidomide

• Dexamethasone

• Bortezomib

• Daratumumab

proteasomes:  
"ubiquitin"

↓  
CD38 ⊖



MM: Plasma BM >10% + Mprtn >3g/dl + CRAB

MGUS: " <10% + " <3g/dl CRAB ⊖

Smouldering MM: Plasma BM >10% + >3g/dl CRAB ⊖


Waldenström's macroglobulinemia: IgM

# ANTI-PLATELETS: PHARMACOLOGY



**PAR-1 INHIBITOR:**  
 AtoPaxar  
 VoraPaxar

# Coagulation cascade




Factor V Leiden  
 - mc disorder  
 ↑ coag

Production of mutant factor V (guanine → adenine DNA point mutation → Arg506Gln mutation near the cleavage site) that is resistant to degradation by activated protein C. Complications include DVT, cerebral vein thrombosis, recurrent pregnancy loss.

ΔFS08  
 ↳ CP

# ANTICOAGULANTS-PHARMACOLOGY



*Purple toe sx / dermal skin necrosis*

**Ciraparantag: antidote → f xa ⊖ / DTI**

# APPROACH TO BLEEDING DISORDERS

Petechiae **(Pit)**  
 Purpura  
 BT

**VWD - mc**  
 BT + aPTT prolonged **vWF + f8**  
 Epistaxis / menorrhagia/ high bleeding after procedures  
 Chr 12 AD/ Ristocetin aggregation test IOC  
 TOC: Desmopressin (↑vWF)  
 Type 1: ↓↓ quantity  
 Type 2: ↓ quality  
 Type 3: **AR** absence ~~AR~~  
 2N (f8 release x-AR): **RIPA N**

Ecchymosis  
 Hemarthrosis  
 CT **Coag factors**

**PLATELET COUNT**

**PT / aPTT**

**NORMAL**

**REDUCED**

**PT RAISED**

**aPTT raised**

**Both normal**

**Both raised**

Abn ADP/collagen Aggregation  
 GpIIb/IIIa ⊖  
 Glanzmann

GpIb ⊖: Bernard Soulier  
 Abn Ristocetin Aggregation,  
 Giant platelets

**(extrinsic)**  
**f7 EARLY**  
 vit K def / warfarin toxicity  
 ↓  
 2/7/9/10

**(intrinsic)**  
 Hemophilia  
 A - f8  
 B - f9 } xLR  
 C - f11 → AR

APLA  
 f13 / Laki Lorand factor

f10 def  
 fibrinogen def


**ITP**  
 anti-GpIIb  
 Immature Platelet >6%  
 1st: Steroids  
 ↓  
 Splenectomy  
 Oprelevkin IL-11 ⊕  
 Romiplostim, Eltrombopag TPO ⊕  
 Fostamatinib tyrosine kinase ⊖

f12 → deficiency  
 (X) bleed in vivo  
 Useless

**DIC**  
 PT, aPTT, D-Dimer, thrombocytopenia  
**Oozing from puncture sites**  
 D/D - Hemolytic transf rxn

# BLOOD GROUPING

| Blood Group               | Antigens       | Antibodies                    |
|---------------------------|----------------|-------------------------------|
| A                         | <i>h, a</i>    | <i>anti-b</i>                 |
| B                         | <i>h, b</i>    | <i>anti-a</i>                 |
| <i>recipient</i> AB       | <i>h, a, b</i> | -                             |
| <i>donor</i> O            | <i>h</i>       | <i>antia, anti-b</i>          |
| <u>Bombay</u> Blood Group | -              | <i>anti-h, anti-a, anti-b</i> |



*A-ve*

*A +ve*

*B-ve*

*B +ve*

*O +ve*

*Bombay*

Resistance to P.vivax and P.knowlesi : *Duffy Ag absent*

McLeod syndrome : *Kell Ag*

Antigens adsorbed from plasma: *Lewis Ag*

*Rh - 2*

*ABO - 9*

*h - 19*

# TRANSFUSION MEDICINE

**CPD: Citrate Phosphate Dextrose 3wk**

**CPDA: + Adenine 5w**

**SAGM: Saline Adenine Glucose Mannitol 6wk**

**Massive transfusion: >10U/24hrs**

**Ca: ↓ Mg ↓** (∴ sequestered)

**K: ↓ → ↑K<sup>+</sup>** (∴ RBC lysis)

**Acid-base: metab acidosis → metab alkalosis** (∴ HCO<sub>3</sub>)

**MCC of death: Dilution coagulopathy**

| Complication                              | Signs/Symptoms  | Treatment  |
|---|---|--|
| <b>Febrile NHTR (MC)</b>                  | Fever, Chills, Malaise<br><b>WBCs</b>   | Supportive-<br><u>acetaminophen</u>  |
| <b>Hemolytic transfusion rxn</b>          | Fever, chills, pain at the site of reaction, nausea/vomiting, shock, dark urine | <b>STOP the transfusion</b><br>IV fluids +/- diuretics<br><b>MCC: ABO incompat</b> |
| <b>Allergic</b>                           | Urticaria, pruritis, hives<br><b>↑ IgA deficiency</b>                           | Symptomatic-<br><u>antihistamines.</u>   |
| <b>TRALI</b><br>(E in hrs) anti-HLA donor | Dyspnea, <b>hypoxemia</b> ,<br><b>bilateral chest infiltrates</b> crepts        | <b>STOP the transfusion</b><br>airway control,<br>supportive care                  |
| <b>TACO</b>                               | Dyspnea, <b>edema</b> ,<br><b>JVP Raised</b>                                    | Slow infusion +<br>Diuretics   |

**Leukoreduction filter**

↓ WBC  
↓ febrile  
↓ **CMV**  
↓  
mc blood transfusions

**PT agitator**



**① prevention**  
**prospective screening**  
**x dengue &**


|                       | Storage temp                                  | Shelf life     | Transfuse within | Increase by                                   |
|-----------------------|---|----------------|------------------|---|
| Whole blood / PRBC    | <b>2-6 °C</b>                                 | <b>42d max</b> | <b>4hrs</b>      | <b>1g/dl</b><br><b>3% Hct</b>                 |
| Platelet: Pooled SDAP | <b>24-28 °C</b><br>↑ bact contam <sup>v</sup> | <b>5d</b>      | <b>30min</b>     | <b>↑ 5-10k</b>                                |
| FFP Cryoppt           | <b>-18 °C</b><br><b>-30 °C</b>                | <b>1yr</b>     | <b>30 min</b>    | <b>Cryoppt:</b><br>Fibrinogen<br>vWF - f8 f13 |

**Screen for: HIV/ HBV/ HCV/ SYPHILIS/ MALARIA**

- Massive transfusions
- Drowning
- Tumor lysis Sx
- Refeeding Sx

# MISCELLANEOUS

**ESR**




200x dilution

20x dilution

**Plt**



Rees Ecker fluid

## Neubauer chamber





Plt : RBC chamber

| Wintrobe   | Westergren   |
|--|--|
| <ul style="list-style-type: none"> <li>• Tube is closed at lower end &amp; open at upper end</li> <li>• It contains less vol. blood sample</li> <li>• EDTA as anticoagulant</li> <li>• Values are less sensitive</li> <li>• Tube is 11 cm.</li> <li>• Dia-2.5mm</li> </ul> | <ul style="list-style-type: none"> <li>• The tube is opened at both ends</li> <li>• It contains large vol. of blood sample</li> <li>• Sodium citrate as anticoagulant</li> <li>• Values are more sensitive</li> <li>• Tube is 30 cm long</li> <li>• Diameter internal-2.5mm</li> </ul> |



# TUMOR LYSIS



Svc syndrome: SVC stent

Acute back pain due to bone mets: Dexamethasone

Palliative: RT ← MRI

TEG: Thromboelastography

↓  
all steps of coagn pathway

ROTEM

| TEG                     | ROTEM                       | Description  | Normal     | Abnormality: Cause  | Treatment                     |
|-------------------------|-----------------------------|--|------------|---|-------------------------------|
| Reaction Time (R value) | Clotting Time (CT)          | Time till initiation of fibrin clot formation                                  | 5 - 10 min | $\uparrow$ R value:<br>$\downarrow$ factors                         | FFP<br>protamine              |
| K value                 | Clot Formation Time (CFT)   | Time to achieve 20 mm clot on assay representing thrombin-platelet interaction | 1 - 5 min  | $\uparrow$ K/CFT value:<br>$\downarrow$ fibrinogen                  | Cryoprecipitate<br>Fibrinogen |
| $\alpha$ -angle         | $\alpha$ -angle             | Rate at which fibrin cross-linking occurs                                      | 45 - 75°   | $\downarrow$ $\alpha$ angle:<br>$\downarrow$ fibrinogen             | Cryoprecipitate<br>Fibrinogen |
| Maximum Amplitude (MA)  | Maximum Clot Firmness (MCF) | Maximum strength of clot   | 50 - 75 mm | $\downarrow$ MA/MCF:<br>$\downarrow$ platelet count and/or function | Platelets<br>DDAVP            |
| LY-30                   | Clot Lysis (CL)             | Degradation of clot 30 minutes after MA/MCF                                    | 0 - 10%    | $\uparrow$ LY-30/CL:<br>$\uparrow$ clot breakdown                   | TXA<br>Amicar                 |

R  
K ] → Coagn factors

$\alpha$  → (+) fibrinogen

Ma → Plt<sup>22</sup>

MAP

Ly 30 → fibrinolysis